The pharmaceutical company said its board will consider 2-for-1 stock split on 13 November 2021.
The board will consider splitting each share of face value Rs 2 each into two shares of face value of Re 1 each.On 13 November 2021, the company's board will also consider Q2 results and interim dividend.
On a consolidated basis, net profit of IPCA Laboratories declined 31.26% to Rs 306.66 crore on 2.05% rise in net sales to Rs 1565.79 crore in Q1 June 2021 over Q1 June 2020.
IPCA is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. It is one of the world's largest manufacturers and suppliers of over a dozen APIs.
Shares of IPCA Laboratories were down 1.03% at Rs 2,322. The stock hit a high of Rs 2,397.40 and a low of Rs 2,281.45 so far during the day.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
